, Tracking Stock Market Picks
Enter Symbol:
Rating: GHDX
Buy $44

Genomic Health, Inc. (NASDAQ: GHDX) upgraded to Buy with price target $44 by Canaccord Genuity

Wednesday,  Jan 6, 2016  9:25 AM ET by Lynn Gilbert

Canaccord Genuity upgraded Genomic Health, Inc. (NASDAQ: GHDX) to Buy with price target
$44. Previously, Canaccord Genuity rated Genomic Health, Inc. (NASDAQ: GHDX) to Hold with price target $26 on 08/05/2015, when the stock price was valued at $25.23.

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The Oncotype DX assay represents the first diagnostic gene expression test on the market that provides consistent results across multiple independent trials having breast cancer patients, including a large validation study of The New England Journal of Medicine.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy